Ophthalmology and ASC Sales: Premiums from Multi-Location Platforms
Ophthalmology has emerged as one of the most actively consolidated specialties in healthcare. Private equity platforms have spent years acquiring practices and ambulatory surgery centers (ASCs), building regional and national networks that deliver eye care at scale. For practice owners in the $2M to $20M revenue range, this creates exceptional exit opportunities but also complexity. Multi-location platforms command significant premiums over single-site practices, and ASC ownership can dramatically impact valuation.
Why Ophthalmology Is a Hot M&A Sector
Ophthalmology combines several characteristics that make it attractive to buyers. Age-related eye conditions including cataracts, glaucoma, and macular degeneration increase with age, so as the population ages, demand grows predictably. Cataract surgery, LASIK, and premium lens implants generate strong margins, particularly when performed in practice-owned ASCs. Many eye conditions require ongoing management, creating predictable patient relationships. Most ophthalmology practices are independently owned, giving consolidators a long runway to build scale. Practices that own ASCs capture facility fees that would otherwise go to hospitals, dramatically improving economics.
Current Multiples for Ophthalmology Practices
| Practice Profile | Typical EBITDA Multiple |
|---|---|
| Solo practice, no ASC | 4x to 6x |
| Group practice (2 to 4 MDs), no ASC | 5x to 7x |
| Group practice with ASC ownership | 7x to 10x |
| Multi-location platform with ASC(s) | 9x to 13x |
| Retina subspecialty (standalone) | 8x to 12x |
The ASC Premium: Why It Matters
Ambulatory surgery centers are the key differentiator in ophthalmology valuations. When cataract surgery is performed in a hospital, the hospital collects the facility fee, often $2,000 to $4,000 per case. When performed in a practice-owned ASC, the practice captures that revenue. ASC-based surgery typically generates 40 to 60% margins compared to 15 to 25% for clinic-only practices. Buyers want ASC access to improve economics across their portfolio. A practice performing 500 cataract surgeries annually at a hospital generates minimal facility revenue. The same practice with an owned ASC might generate $1.5M to $2M in additional annual revenue at high margins. This explains why ASC-owning practices command 2 to 4 additional multiple turns over comparable practices without ASCs.
Within ophthalmology, retina commands the highest multiple at 8x to 12x EBITDA. Retina specialists treat serious conditions including AMD and diabetic retinopathy with expensive injectable medications that generate significant revenue, and limited fellowship training creates supply constraints. Multi-location practices command premiums because they provide geographic coverage and patient convenience, demonstrate the model is replicable, show operational scale through centralized billing and management, demonstrate de novo potential, and often have or can justify ASC development.
Timing the Ophthalmology Market in 2026
Major platforms including EyeCare Partners, US Eye, and Retina Consultants of America remain acquisitive in 2026. PE capital allocated to ophthalmology remains substantial and demographics continue to drive volume growth. However, roll-up maturation in some markets may compress tuck-in multiples, platform deals are increasingly rare as consolidation progresses, and competition for retina practices has intensified. For practices with ASC ownership, strong volume, and multi-location presence, 2026 offers attractive exit conditions. Smaller practices without ASCs may face a more competitive buyer market. Schedule a confidential valuation consultation to understand your specific situation.
FAQs
Why is ASC ownership so important to ophthalmology valuations?
ASCs capture facility fees of $2,000 to $4,000 per cataract surgery that would otherwise go to hospitals. This dramatically improves practice economics. Practices with ASC ownership generate higher margins and command 2 to 4 additional multiple turns.
Can I sell my ophthalmology practice without an ASC?
Yes, but valuations will be lower at 4x to 7x versus 7x to 13x for ASC-owning practices. Buyers may still be interested, particularly if your market has ASC development potential.
Should I develop an ASC before selling?
Possibly. ASC development takes 18 to 24 months and requires capital and expertise. If you have time and resources, ASC ownership can significantly increase valuation. Alternatively, buyers may develop ASCs post-acquisition but you will not capture that premium.
What transition period should I expect?
Most ophthalmology deals require 2 to 3 years of post-sale employment, particularly for high-producing surgeons. Practices with strong associate teams may negotiate shorter transitions.
Recommended Reading
- Healthcare Practice Valuation Multiples 2026 — Broad healthcare sector benchmarks across all major specialties.
- Private Equity Rollovers: How to Sell Your Company Twice — Understand equity rollover structures common in ophthalmology deals.
- How to Sell Your Business to Private Equity — How PE platforms work and what to expect.
- Women's Health Practices: OB/GYN Exit Guide — Another healthcare specialty with similar platform consolidation dynamics.
- EBITDA Multiples by Industry (2026) — Cross-industry valuation context.
Key Takeaways
- ASC ownership is the single most important valuation driver in ophthalmology, adding 2 to 4 multiple turns.
- Multi-location platforms command 9x to 13x EBITDA while solo practices without ASCs trade at 4x to 6x.
- Retina subspecialty practices command premium multiples of 8x to 12x due to high revenue per patient and limited supply.
- Provider depth and subspecialty diversification reduce key-person risk and attract broader buyer interest.
- Roll-up activity continues in 2026 but platform deals are becoming rarer as consolidation progresses.
- Start preparation 12 to 24 months before your target exit, particularly if ASC development or provider recruitment is needed.